{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 22 of 169', 'Panel 3 Schedule of trial procedures: maintenance treatment period and follow-up', 'Maintenance treatment period', 'FU1\u00b2', 'Visit', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30\u00b9', '31', 'Week', '18', '20', '22', '24', '26', '28', '30', '32', '34', '36', '38', '40', '42', '44', '46', '48', '50', '52', '66', 'Visit window (days)', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', 'Trial products (Section 9)', 'IMP administration and compliance', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medication/procedures', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Investigator assessments of efficacy (Section 10.3.1)', 'IGA', 'X3', 'X3', 'X3', 'X3', 'X\u00b3', 'X\u00b3', 'X\u00b3', 'X3', 'X\u00b3', '3', 'X3', 'X3', 'X3', 'X\u00b3', 'X\u00b3', 'X\u00b3', 'X\u00b3', 'X', 'EASI', 'X\u00b3', 'X\u00b3', 'X\u00b3', 'X3', 'X\u00b3', 'X\u00b3', 'X\u00b3', 'X3', 'X\u00b3', 'X3', 'X\u00b3', 'X\u00b3', 'X3', 'X3', 'X\u00b3', 'X\u00b3', 'SCORAD', 'X', 'X', 'X', 'X', 'Subject assessments of efficacy (Section 10.3.2)', 'eDiary4', 'POEM and DLQI', 'X', 'EQ-5D-5L and HADS', 'SF-36 and WPAI-GH', 'TSQM', 'X', 'Safety assessments (Sections 10.4 and 11)', 'Vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical examination', 'ECG', 'Urine pregnancy test', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 23 of 169', 'Panel 3 Schedule of trial procedures: maintenance treatment period and follow-up (continued)', 'Maintenance treatment period', 'FU1\u00b2', 'Visit', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30\u00b9', '31', 'Week', '18', '20', '22', '24', '26', '28', '30', '32', '34', '36', '38', '40', '42', '44', '46', '48', '50', '52', '66', 'Safety assessments (Sections 10.4 and 11)', 'Serum chemistry, haematology, and IgE', 'X', 'X', 'X', 'X', 'X', 'Urinalysis', 'Pharmacokinetics', 'ADA', 'Adverse events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Other assessments (Section 10.5)', 'Skin swabs (S. aureus)', 'Skin swabs (microbiome)', 'Serum biomarkers (small panel)', 'Serum biomarkers (large panel)', 'Photography5', 'X', '1) Assessments also to be done at an early termination visit.', '2) Subjects will have a safety follow-up (FU1) 16 weeks after last injection of IMP; this is considered the end of trial visit. For subjects who are', 'enrolled', 'into', 'the', 'long-term extension trial (conducted under a separate protocol [LP0162-1337, ECZTEND]), the end of trial visit will be the last visit in trial LP0162-1325', 'before transfer to the extension.', '3) Subjects who meet the following criteria will be transferred to open-label treatment (tralokinumab 300 mg Q2W with optional use of TCS [Panel 4]):', 'Subjects with IGA=0 at Week 16: IGA of at least 2 and not achieving EASI75 over at least a 4-week period (i.e., over 3', 'consecutive', 'visits).', 'Subjects with IGA=1 at Week 16: IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e., over 3 consecutive visits).', 'Subjects with IGA >1 at Week 16: not achieving EASI75 over at least a 4-week period (i.e., over 3 consecutive visits).', 'The first injections of open-label treatment will be given at the visit in the maintenance period where the subject meets these criteria.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}